V-Set Domain-Containing T-Cell Activation Inhibitor 1
"V-Set Domain-Containing T-Cell Activation Inhibitor 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A B7 antigen subtype that inhibits the costimulation of T-cell activation, proliferation, cytokine production and development of cytotoxicity. The over expression of this protein in a variety of tumor cell types suggests its role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060907
|
| MeSH Number(s) |
D12.776.467.150.900 D12.776.543.095.900 D23.050.301.285.900 D23.529.168.900
|
| Concept/Terms |
V-Set Domain-Containing T-Cell Activation Inhibitor 1- V-Set Domain-Containing T-Cell Activation Inhibitor 1
- V Set Domain Containing T Cell Activation Inhibitor 1
- Immune Costimulatory Protein B7-H4
- Immune Costimulatory Protein B7 H4
- T-Cell Costimulatory Molecule B7x
- T Cell Costimulatory Molecule B7x
- B7H4 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "V-Set Domain-Containing T-Cell Activation Inhibitor 1".
Below are MeSH descriptors whose meaning is more specific than "V-Set Domain-Containing T-Cell Activation Inhibitor 1".
This graph shows the total number of publications written about "V-Set Domain-Containing T-Cell Activation Inhibitor 1" by people in this website by year, and whether "V-Set Domain-Containing T-Cell Activation Inhibitor 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "V-Set Domain-Containing T-Cell Activation Inhibitor 1" by people in Profiles.
-
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
-
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171.
-
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
-
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol. 2021 07; 113:20-27.
-
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. Cancer Discov. 2020 12; 10(12):1872-1893.
-
Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight. 2019 10 03; 4(19).
-
Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 09; 158(3):911-919.e6.
-
B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Hum Pathol. 2016 11; 57:1-6.
-
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunol Res. 2015 Aug; 3(8):849-54.
-
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol. 2012 Oct 15; 189(8):4165-74.